US Stock MarketDetailed Quotes
ACHV Achieve Life
- 3.520
- -0.210-5.63%
Close Jan 8 16:00 ET
- 3.501
- -0.019-0.54%
Post 20:01 ET
121.05MMarket Cap-3.14P/E (TTM)
3.830High3.520Low246.79KVolume3.670Open3.730Pre Close897.89KTurnover0.85%Turnover RatioLossP/E (Static)34.39MShares5.59052wk High3.86P/B102.39MFloat Cap3.42052wk Low--Dividend TTM29.09MShs Float1856247.281Historical High--Div YieldTTM8.31%Amplitude2.000Historical Low3.638Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Achieve Life Stock Forum
Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission
Tuesday, 7th January at 8:30 am
Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure Requirement for NDA Submission
ORCA-OL Long-Term Exposure Timelines Remain on Track with No Safety Concerns Identified
Planned Cytisinicline NDA Submission on...
Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes
Achieve Life Sciences has initiated the ORCA-OL clinical trial to evaluate the long-term safety of cytisinicline, a treatment for smoking and nicotine dependence. The open-label trial involves 29 U.S. sites and aims to collect data required for a New Drug Application (NDA) submission expected in the first ...
NEWS
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0...
No comment yet